lambeth-hp-logo
    Facebook-f X-twitter Instagram Linkedin
    lambeth-hp-logo

      Bupropion

      Generic Name: Bupropion
      Common Brand Names: Wellbutrin, Zyban, Aplenzin

      Introduction

      Bupropion is an atypical antidepressant and smoking cessation aid. It is used to treat major depressive disorder (MDD), seasonal affective disorder (SAD), and as a smoking cessation aid. It is also used off-label for weight loss and to help manage attention-deficit hyperactivity disorder (ADHD).

      Conditions of Use (Indications)

      1. Major Depressive Disorder (MDD): Used as a first-line treatment for patients with depression.
      2. Smoking Cessation: Sold under the brand name Zyban for smoking cessation.
      3. Seasonal Affective Disorder (SAD): An option for treating seasonal depression.
      4. Off-Label Uses: Weight loss, ADHD, and anxiety disorders.

      Mechanism of Action

      Bupropion works by inhibiting the reuptake of dopamine and norepinephrine in the brain. This leads to increased concentrations of these neurotransmitters in the synaptic cleft, which can alleviate symptoms of depression and promote smoking cessation.

      Side Effects

      1. Common:
      • Insomnia, dry mouth, and headache.
      • Weight loss and reduced appetite.

       

      • 2. Serious:
      • Seizures (especially in those with eating disorders or a history of seizures).
      • Increased risk of suicidal thoughts in young adults.
      • Hypertension, especially with higher doses.

      Harmful Interactions

      1. Monoamine Oxidase Inhibitors (MAOIs): Can cause hypertensive crises if used in combination.
      2. Other Antidepressants: Increased risk of serotonin syndrome when combined with certain SSRIs or SNRIs.
      3. Alcohol: Increases the risk of seizures, especially during acute alcohol withdrawal.

      Contraindications

      1. Seizure disorders (e.g., epilepsy).
      2. Eating disorders like bulimia or anorexia.
      3. Current use of monoamine oxidase inhibitors (MAOIs).
      4. Known hypersensitivity to bupropion.

      Latest References

      1. Patel, A. K., et al. (2023). “Bupropion in Depression and Smoking Cessation: A Review of Efficacy and Safety.” Journal of Psychiatric Research, DOI: 10.1016/j.jpsychiatres.2023.04.002
      2. FDA. (2022). “Bupropion and the Risk of Seizures.” U.S. Food and Drug Administration.

        Recent Stories